Optimizerx CORP Form 4 insider transactions

OptimizeRx's Chief Finance & Strategy Officer, Edward Stelmakh, converted restricted stock units into common stock, increasing his direct beneficial ownership.

OptimizeRx Chief Product & Tech Officer Doug Besch converted restricted stock units into common stock and subsequently sold a portion to cover tax obligations.

OptimizeRx's Chief Business Officer, Andrew J. D'Silva, received a grant of 10,417 restricted stock units and 23,437 stock options.

OptimizeRx Director Patrick D. Spangler sold 11,120 shares of common stock for a weighted average price of $17.49 per share.

OptimizeRx CEO Stephen L. Silvestro received significant equity grants, including restricted stock units and stock options, as part of a pre-planned transaction.

OptimizeRx's Chief Legal & Admin Officer, Marion Odence-Ford, was granted 15,625 restricted stock units and 35,156 stock options.

Edward Stelmakh, CFO/COO of OptimizeRx Corp, was granted 15,625 restricted stock units and options for 35,156 shares of common stock.

OptimizeRx Chief Commercial Officer Theresa Greco received 15,625 restricted stock units and 35,156 stock options as part of her compensation.

OptimizeRx's Chief Product & Technology Officer, Doug Besch, was granted restricted stock units and stock options.

OptimizeRx Corporation's Director, Cathy Klema, was granted 9,868 restricted stock units (RSUs) on June 11, 2025, as part of her compensation, aligning her interests with shareholders.

OptimizeRx Corp. Director James Paul Lang was granted 9,868 restricted stock units, increasing his beneficial ownership to 399,320 shares.

OptimizeRx Corp. Director Patrick D. Spangler was granted 9,868 restricted stock units, increasing his direct beneficial ownership to 55,335 shares.

OptimizeRx Corporation's Director, Ellen O'Connor Vos, was granted 9,868 restricted stock units (RSUs) on June 11, 2025, as part of her compensation.

OptimizeRx Corp. Director Gregory D. Wasson was granted 9,868 restricted stock units, aligning his interests with shareholders and increasing his beneficial ownership to 57,183 shares.

Theresa Greco, Chief Commercial Officer of OptimizeRx Corp, reports the acquisition of restricted stock units and stock options.

Stephen L. Silvestro, Chief Commercial Officer of OptimizeRx Corp, reports the acquisition of restricted stock units and stock options.

Director James Paul Lang purchased 321,408 shares of OptimizeRx Corp (OPRX) at a weighted average price of $7.6033 on March 14, 2025.

Stephen L. Silvestro, Chief Commercial Officer of OptimizeRx Corp, reports the vesting of restricted stock units and subsequent tax withholding.

Marion Odence-Ford, Chief Legal Officer & CHRO of OptimizeRx Corp, reports the vesting and subsequent tax withholding of restricted stock units.

OptimizeRx CEO William Febbo disposed of 401 shares of common stock on February 14, 2025, to satisfy tax withholding obligations.

Edward Stelmakh, CFO/COO of OptimizeRx Corp, disposed of 2,156 shares of common stock on February 15, 2025, to cover tax withholding obligations.

Doug Besch, Chief Product Officer of OptimizeRx Corp, disposed of 1,386 shares of common stock on February 15, 2025, to satisfy tax withholding obligations.

Stephen L. Silvestro, Chief Commercial Officer of OptimizeRx Corp, reports the disposition of 2,298 shares of common stock to cover tax withholding obligations.

Marion Odence-Ford, Chief Legal Officer & CHRO of OptimizeRx Corp, disposed of shares to cover tax withholding obligations.

Marion Odence-Ford, General Counsel and CCO of OptimizeRx Corp, exercised stock options and disposed of shares to cover tax obligations on February 11, 2025.

Director Cathy Klema reports the vesting and conversion of restricted stock units into common stock of OptimizeRx Corp.

Edward Stelmakh, CFO/COO of OptimizeRx Corp, reports the acquisition of restricted stock units and stock options.

OptimizeRx's CFO, Edward Stelmakh, has amended a previous SEC filing to correct an understatement of his directly owned shares.

OptimizeRx's Chief Commercial Officer, Stephen L. Silvestro, was granted restricted stock units and stock options on December 23, 2024.

Theresa Greco, Chief Commercial Officer of OptimizeRx Corp, was granted stock options and restricted stock units on December 23, 2024.